Biotech Values

[pcrutch]

3. Chance for ARRY to take one MEK162 indication and co-develop for significantly increased royalty beyond typical double-digit royalty with ARRY investment capped. ARRY in active discussions with NVS to select this indication and it would be a fast to market opportunity.

Any idea on what indication? Hmmmm...